Insider trade

Officer purchased ~$150K of HUM shares in the open market

Traded Feb 23, 2026 · Filed Feb 25, 2026

~$150K
Reported value · 810 sh @ $185.205: 12K
Holds after · shares reported: +109.6%
stock since the trade · S&P 500 +12.0%, $181.16 → $379.68 on Oct 1

Why it stands out

Humana's President, CenterWell spent $150K of their very own money to buy Humana shares. Their pile of Humana shares grew by 8%.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Feb 23, 2026
Reporting period: Not applicable
Filed with the SEC: Feb 25, 2026

Officer$100K–$500KHoldings +8%

Context

Classification

open market purchase

Code P — open-market or private purchase

Absolute commitment

~$150,016

Shares × reported transaction price

Size band

$100K–$500K

Ownership change

+7.5%

Purchase shares ÷ estimated pre-transaction holdings, from the filing

Rarity

Not enough history to judge

Confirmed open-market purchases by the same insider in the available history

Cluster activity

No other insider purchases within 30 days

Distinct insiders at the same issuer with confirmed open-market purchases

Size vs officer pay

This purchase equals about 1.6% of the average reported total pay of the company's named executive officers other than the CEO, fiscal 2025 ($9.39M)

An average across the officers named in the pay versus performance table of the company's proxy statement (DEF 14A), filed 2026-03-06. This person may not be one of them, so it is not their own pay. A size comparison, not a judgement

Timing vs results

12 days after results of Feb 11, 2026, 65 days before results of Apr 29, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Price at the time

Closed at $181.16 on Feb 23, 2026, within 4% of its 52-week low, after a 35% drop over the previous 30 trading days

52-week range $175.40 (Feb 11, 2026) to $312.00 (Sep 4, 2025), 4% of the way up, from 251 adjusted closes. 30 trading days earlier: $277.57 on Jan 8, 2026. Describes the past only, not a forecast

Planned / mechanical clue

None found in footnotes

Only flagged when a footnote says so; never inferred

Securities lawsuit open at the trade date

A securities lawsuit naming the company as a defendant was filed on Jul 31, 2024 in the U.S. District Court, D. Delaware. A filing is an allegation, not a finding.

2 such cases were open. Marathe v. Humana Inc., docket 1:24-cv-00898, via CourtListener (court records). Nature of suit 850, company named as first defendant

After it was reported

After	Stock	S&P 500	Difference
7 days	-3.3%	-1.2%	-2.1%
30 days	-11.2%	-8.3%	-2.8%
90 days	+63.9%	+8.9%	+55.1%
180 days	+108.6%	+11.1%	+97.5%

Past results only. Not a forecast.

Source receipt

Record ID: 0001969331-26-000002
Filed / recorded: Feb 25, 2026, 4:48 PM UTC
Added to OQRO: Oct 2, 2026, 12:28 PM UTC
Parser: form4-xml-v1
Data quality: Verified: identifiers matched exactly
Issuer: HUMANA INC
Issuer CIK: 49071
Ticker: HUM
Reporting person: Sanjay K Shetty
Relationship: Officer
Officer title: President, CenterWell
Security: Humana Common
Table: Non-derivative (Table I)
Transaction date: Feb 23, 2026
Transaction code: P
Shares / units: 810
Price per share: $185.205
Acquired / disposed: Acquired (A)
Shares owned after: 11,657
Ownership form: Direct
Amendment: No

Footnotes from the filing

Shares purchased on open market at reported price.
Includes 8,818 restricted stock units representing a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1)&(3) under the Company's 2019 Amended & Restated Plan.